This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Oncothyreon Initiates Phase 1/2 Trial Of PX-866 In Combination With Vemurafenib

SEATTLE, May 31, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced the initiation of a Phase 1/2 trial of PX-866 in combination with vemurafenib (Zelboraf®).  PX-866 is Oncothyreon's investigational small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.  Vemurafenib is a kinase inhibitor indicated for the treatment of unresectable or metastatic melanoma with the BRAF V600E mutation.

The Phase 1 portion of this trial will evaluate the safety and tolerability of PX-866 in combination with twice daily oral administration of vemurafenib in up to 36 patients with any BRAF-mutant cancer.  The trial will use a dose-escalation design to evaluate up to three dose levels of PX-866 with up to two dose levels of vemurafenib to determine the maximally tolerated or recommended dose of both PX-866 and vemurafenib to be used in Phase 2.  The Phase 2 portion of the trial will compare the anti-tumor activity and safety of PX-866 and vemurafenib at the doses recommended from Phase 1 with vemurafenib alone administered at the approved dose.  This randomized Phase 2 trial is expected to enroll 110 patients with advanced BRAF-mutant melanoma and has a primary endpoint of progression-free survival.

This Phase 1/2 trial is being conducted in collaboration with the Melanoma Research Foundation Breakthrough Consortium (MRFBC).  Lynn M. Schuchter, M.D., Chief of the Hematology Oncology Division and leader of the melanoma program at the Abramson Cancer Center of the University of Pennsylvania, a member of the MRFBC, said, "While vemurafenib has significantly prolonged the lives of patients with BRAF-mutant melanoma, many patients develop resistance.  Preclinical evidence suggests that the PI-3 kinase pathway may contribute to this resistance, and we are therefore excited to begin this study."

"We are grateful to the MRFBC for proposing and performing this study," said Robert L. Kirkman, M.D., President and Chief Executive Officer of Oncothyreon.  "With the initiation of this trial, Oncothyreon is now conducting five Phase 2 trials of PX-866 in six different tumor types, a broad development program reflecting our enthusiasm for this product candidate."

About the Melanoma Research Foundation Breakthrough Consortium

The mission of the Melanoma Research Foundation Breakthrough Consortium (MRFBC) is to accelerate research and development of the most promising therapeutics in melanoma to deliver curative treatment options to patients.  The Consortium was created in 2010 and consists of basic scientists, translational researchers and investigators from 13 centers of excellence in melanoma, including all of the centers designated by National Cancer Institute as a Specialized Program of Research Excellence (SPORE) in skin cancer.  The MRFBC works through collaborative private, public and nonprofit partnerships to facilitate, conduct or enhance the development of the most promising combination therapies - a strategy which has been shown to be the cornerstone of success in treating diseases such as TB and HIV.  In addition to support of high-impact clinical trials, key initiatives include preclinical testing of compounds in combination, development of a collaborative virtual specimen bank operating under common standards, and development of a translational research agenda across trials.  Clinical trials supported by the MRFBC are opening this year.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs